Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxVRCDF -60.53% EV-to-EBITDA is -0.60 as of Aug. 02, 2026. The stock has 3 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Verici Dx ranks worse than 840335.29% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Verici Dx's enterprise value is $3.78 Mil.
Verici Dx's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.34 Mil. Therefore, Verici Dx's EV-to-EBITDA for today is -0.60.
The historical rank and industry rank for Verici Dx's EV-to-EBITDA or its related term are showing as below:
VRCDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.81 Med: -0.64 Max: 0.42
Current: -0.96
During the past 6 years, the highest EV-to-EBITDA of Verici Dx was 0.42. The lowest was -2.81. And the median was -0.64.
VRCDF's EV-to-EBITDA is ranked worse than 100% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.06
vs VRCDF: -0.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Verici Dx's share price for today is $0.003.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.013.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Verici Dx's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Verici Dx's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Verici Dx's EV-to-EBITDA falls into.
Verici Dx's current Enterprise Value is $3.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (VRCDF) has a EV-to-EBITDA of -0.60 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Verici Dx. According to the industry distribution chart, Verici Dx ranks #999999 out of 119 companies in the Medical Diagnostics & Research industry.
Is Verici Dx's EV-to-EBITDA too high?
Verici Dx's current EV-to-EBITDA is -0.60. Based on the distribution chart, Verici Dx ranks #999999 out of 119 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #999999 out of 119 companies for EV-to-EBITDA. This places Verici Dx in the lower half of its industry. The industry median EV-to-EBITDA is 15.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.06, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Verici Dx. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current EV-to-EBITDA is -0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current EV-to-EBITDA of -0.60. The current EV-to-EBITDA is -0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Verici Dx (VRCDF), the current EV-to-EBITDA is -0.60 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
